203435-09-0

Basic information

• Product Name: 2,3,4,6-tetra-O-benzoyl-α,b-D-galactopyranosyl trichloroacetimidate
• Synonyms: 2,3,4,6-tetra-O-benzoyl-α,b-D-galactopyranosyl trichloroacetimidate
• CAS NO: 203435-09-0
• Molecular Weight: 740.978
• Mol File: 203435-09-0.mol

Chemical Properties

• CAS DataBase Reference: 2,3,4,6-tetra-O-benzoyl-α,b-D-galactopyranosyl trichloroacetimidate(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3,4,6-tetra-O-benzoyl-α,b-D-galactopyranosyl trichloroacetimidate(203435-09-0)
• EPA Substance Registry System: 2,3,4,6-tetra-O-benzoyl-α,b-D-galactopyranosyl trichloroacetimidate(203435-09-0)

Safety Data

• Hazardous Substances Data: 203435-09-0(Hazardous Substances Data)

Upstream product

• 2592-58-7 1,2,3,4,6-Penta-O-benzoyl-α-D-galactopyranose 
• 98-88-4 benzoyl chloride 
• 627466-84-6 2,3,4,6-tetra-O-benzoyl-D-galactose 
• 545-06-2 trichloroacetonitrile 
• 48149-72-0 (2S,3R,4S,5R,6R)-2-Allyloxy-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol 
• 10257-28-0 D-Galactose 
• 188435-38-3 bromide 2,3,4,6-tetra-O-Bz-α-D-galactopyranosyl bromide 

Downstream Products

• 162710-64-7 O-(2,3,4,6-Tetra-O-benzoyl-β-D-galactopyranosyl)-(1->4)-1,6-anhydro-2,3-O-endo/exo-benzylidene-β-D-mannopyranose 
• 293752-49-5 (1R,2R) 2-hydroxy-cyclohexyl 2,3,4,6-tetra-O-benzoyl-β-D-galactopyranoside 
• 493027-47-7 C₆₂H₆₁NO₁₇Si 
• 904691-44-7 phenyl (2,3,4,6-tetra-O-benzoyl-β-D-galactopyranosyl)-(1->6)-2,3,4-tri-O-benzoyl-1-thio-α-D-mannopyranoside 
• 1390620-14-0 ergosterol-3-O-(2,3,4,6-tetra-O-benzoyl-β-D-galactopyranoside) 

Relevant articles and documents

Carbon tetrachloride-free allylic halogenation-mediated glycosylations of allyl glycosides

The allylic bromination of allyl glycosides is conducted using NBS/AIBN reagents in (EtO)2CO and PhCF3 solutions, without using CCl4 as a solvent. The activated mixed halo-allyl glycosides led to glycosylations, mediated by a triflate, in a latent-active

Convenient synthesis of the immunogenic glycolipid BbGL1

A simple and efficient method to synthesize the immunogenic glycolipid BbGL1 is introduced. Two simple steps were required to obtain the desired product in good yield. First, a highly efficient glycosylation of cholesterol using galactosyl trichloroacetim

Synthesis of a chlorogenin glycoside library using an orthogonal protecting group strategy

Naturally occurring spirostanol saponins bear a chacotriose, α-l-rhamnopyranosyl-(1→2)-[α-l-rhamnopyranosyl-(1→4)] -β-d-glucopyranose residue as the oligosaccharide moiety which is believed to be important for biological activity. Herein the development of a concise, combinatorial method for the synthesis of two series of glycan variants at the 2′ and/or 4′ positions of chacotriose is described and the structure-activity relationships of the glycone part at 3-OH of chlorogenin investigated. These compounds were found to be weakly-cytotoxic toward leukemia cell lines CCRF and HL-20, indicating that the chacotriose moiety is important for anticancer activity.

Highly efficient synthesis and antitumor activity of monosaccharide saponins mimicking components of Chinese folk medicine Cordyceps sinensis

Ergosterol 3-O-β-d-glucopyranoside (1a) and ergosterol 3-O-d-galactopyranoside (1b) were highly efficiently synthesized and evaluated for their inhibitory activities against two tumor cell lines. The structures of these compounds were extensively confirmed by 1H, 13C NMR, IR, and HRMS. Compounds 1a and 1b exhibited interesting cytotoxic profiles. The antitumor activity of compound 1a was higher than that of 1b.

TRITERPENES DERIVATIVES AND USES THEREOF AS ANTITUMOR AGENTS OR ANTI-INFLAMMATORY AGENTS

A compound of formula (1): wherein R1 is selected from the group consisting of H, α-L-Rhamnopyranose, α-D-Mannopyranose, β-D-Xylopyranose, β-D-Glucopyranose, and α-D-Arabinopyranose; R2 is selected from CH3, COOH, CH2OH, COOCH3 and CH2O-α-D-Arabinopyranose; with the proviso that the compound of formula (I) is not a compound of formula (I) wherein R1 is β-D-Glucopyranose and R2 is COOH; wherein R1 is α-L-Rhamnopyranose and R2 is CH3; wherein R1 is β-D-Glucopyranose and R2 is CH2OH; wherein R1 is β-D-Xylopyranose and R2 is CH2OH; wherein R1 is α-L-Rhamnopyranose and R2 is COOCH3, wherein R1 is H and R2 is CH3; wherein R1 is H and R2 is CH2OH; wherein R1 is H and R2 is COOH; or wherein R1 is H and R2 is COOCH3, or a pharmaceutically acceptable salt thereof.